S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Reasons This Sleeping Giant Is About To Wake Up
WARNING: Mandatory U.S. Dollar Recall is Weeks Away (Ad)
MarketBeat Week in Review – 9/18 - 9/22
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
WARNING: Mandatory U.S. Dollar Recall is Weeks Away (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
WARNING: Mandatory U.S. Dollar Recall is Weeks Away (Ad)
Auto workers still have room to expand their strike against car makers. But they also face risks
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Reasons This Sleeping Giant Is About To Wake Up
WARNING: Mandatory U.S. Dollar Recall is Weeks Away (Ad)
MarketBeat Week in Review – 9/18 - 9/22
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
WARNING: Mandatory U.S. Dollar Recall is Weeks Away (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
WARNING: Mandatory U.S. Dollar Recall is Weeks Away (Ad)
Auto workers still have room to expand their strike against car makers. But they also face risks
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Reasons This Sleeping Giant Is About To Wake Up
WARNING: Mandatory U.S. Dollar Recall is Weeks Away (Ad)
MarketBeat Week in Review – 9/18 - 9/22
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
WARNING: Mandatory U.S. Dollar Recall is Weeks Away (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
WARNING: Mandatory U.S. Dollar Recall is Weeks Away (Ad)
Auto workers still have room to expand their strike against car makers. But they also face risks
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Reasons This Sleeping Giant Is About To Wake Up
WARNING: Mandatory U.S. Dollar Recall is Weeks Away (Ad)
MarketBeat Week in Review – 9/18 - 9/22
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
WARNING: Mandatory U.S. Dollar Recall is Weeks Away (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
WARNING: Mandatory U.S. Dollar Recall is Weeks Away (Ad)
Auto workers still have room to expand their strike against car makers. But they also face risks
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
NASDAQ:SPRB

Spruce Biosciences (SPRB) Stock Forecast, Price & News

$2.38
-0.06 (-2.46%)
(As of 09/22/2023 ET)
Compare
Today's Range
$2.34
$2.51
50-Day Range
$2.04
$2.54
52-Week Range
$0.95
$3.57
Volume
69,253 shs
Average Volume
112,988 shs
Market Capitalization
$96.89 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.67

Spruce Biosciences MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
222.1% Upside
$7.67 Price Target
Short Interest
Healthy
0.07% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.40) to ($1.46) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.44 out of 5 stars

Medical Sector

203rd out of 969 stocks

Pharmaceutical Preparations Industry

76th out of 440 stocks


SPRB stock logo

About Spruce Biosciences (NASDAQ:SPRB) Stock

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in South San Francisco, California.

SPRB Price History

SPRB Stock News Headlines

Spruce Biosciences' (SPRB) "Buy" Rating Reaffirmed at HC Wainwright
WARNING: Mandatory U.S. Dollar Recall is Weeks Away
If you have any U.S. dollars in your bank account… You must see this shocking video exposing the government’s new plan to recall the U.S. dollar. According to Business Insider, this recall “could be imminent.” And if you don’t prepare now, you could end up holding a bunch of worthless U.S. dollars.
Spruce Biosciences (SPRB) Gets a Buy from H.C. Wainwright
JMP Securities Sticks to Their Buy Rating for Spruce Biosciences (SPRB)
Analyst Ratings for Spruce Biosciences
WARNING: Mandatory U.S. Dollar Recall is Weeks Away
If you have any U.S. dollars in your bank account… You must see this shocking video exposing the government’s new plan to recall the U.S. dollar. According to Business Insider, this recall “could be imminent.” And if you don’t prepare now, you could end up holding a bunch of worthless U.S. dollars.
Expert Ratings for Spruce Biosciences
JMP Securities Sticks to Its Buy Rating for Spruce Biosciences (SPRB)
Analyst Expectations for Spruce Biosciences's Future
See More Headlines
Receive SPRB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Spruce Biosciences and its competitors with MarketBeat's FREE daily newsletter.

SPRB Company Calendar

Last Earnings
8/14/2023
Today
9/24/2023
Next Earnings (Estimated)
11/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SPRB
Fax
N/A
Employees
32
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$7.67
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+222.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-46,180,000.00
Pretax Margin
-1,166.41%

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.90 per share

Miscellaneous

Free Float
38,309,000
Market Cap
$96.89 million
Optionable
Not Optionable
Beta
2.13
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Michael G. Grey (Age 70)
    Exec. Chairman
    Comp: $70k
  • Dr. Javier Szwarcberg M.D. (Age 53)
    M.P.H., CEO & Director
    Comp: $693.9k
  • Mr. Samir M. Gharib CPA (Age 41)
    CPA, M.B.A., Pres & CFO
    Comp: $536.13k
  • Dr. Ralph William Charlton III (Age 53)
    M.D., Chief Medical Officer
    Comp: $436.38k
  • Ms. P. J. Ramtin
    Sr. VP of Bus. Operations
  • Ms. Heidi Petersen M.P.H.
    Sr. VP of Regulatory & Quality













SPRB Stock - Frequently Asked Questions

Should I buy or sell Spruce Biosciences stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spruce Biosciences in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SPRB shares.
View SPRB analyst ratings
or view top-rated stocks.

What is Spruce Biosciences' stock price forecast for 2023?

6 Wall Street analysts have issued 12 month price targets for Spruce Biosciences' stock. Their SPRB share price forecasts range from $4.00 to $10.00. On average, they anticipate the company's stock price to reach $7.67 in the next twelve months. This suggests a possible upside of 222.1% from the stock's current price.
View analysts price targets for SPRB
or view top-rated stocks among Wall Street analysts.

How have SPRB shares performed in 2023?

Spruce Biosciences' stock was trading at $1.0974 at the beginning of the year. Since then, SPRB shares have increased by 116.9% and is now trading at $2.38.
View the best growth stocks for 2023 here
.

When is Spruce Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our SPRB earnings forecast
.

How were Spruce Biosciences' earnings last quarter?

Spruce Biosciences, Inc. (NASDAQ:SPRB) released its quarterly earnings data on Monday, August, 14th. The company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.37) by $0.05. The business earned $2.17 million during the quarter, compared to analyst estimates of $2.45 million.

When did Spruce Biosciences IPO?

(SPRB) raised $75 million in an initial public offering on Friday, October 9th 2020. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Cowen, SVB Leerink, Credit Suisse and RBC Capital Markets acted as the underwriters for the IPO.

What is Spruce Biosciences' stock symbol?

Spruce Biosciences trades on the NASDAQ under the ticker symbol "SPRB."

Who are Spruce Biosciences' major shareholders?

Spruce Biosciences' stock is owned by many different institutional and retail investors. Top institutional investors include Worth Venture Partners LLC (0.70%), BlackRock Inc. (0.66%), Renaissance Technologies LLC (0.60%), Geode Capital Management LLC (0.55%), Citadel Advisors LLC (0.18%) and State Street Corp (0.15%). Insiders that own company stock include Bali Muralidhar, Camilla V Simpson, Holdings A/S Novo and Venture Fund Iii L Rivervest.
View institutional ownership trends
.

How do I buy shares of Spruce Biosciences?

Shares of SPRB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Spruce Biosciences' stock price today?

One share of SPRB stock can currently be purchased for approximately $2.38.

How much money does Spruce Biosciences make?

Spruce Biosciences (NASDAQ:SPRB) has a market capitalization of $96.89 million. The company earns $-46,180,000.00 in net income (profit) each year or ($1.67) on an earnings per share basis.

How can I contact Spruce Biosciences?

The official website for the company is www.sprucebiosciences.com. The company can be reached via phone at 415-655-4168 or via email at investors@sprucebiosciences.com.

This page (NASDAQ:SPRB) was last updated on 9/24/2023 by MarketBeat.com Staff

My Account -